Hasil Pencarian  ::  Simpan CSV :: Kembali

"ABSTRAKLatar belakang: Peran utama matriks metalloproteinase-9 (MMP-9) adalah mendegradasi matriks ekstraseluler sehingga menyebabkan terjadinya invasi dan infiltrasi sel tumor. Tujuan utama penelitian ini adalah menilai kadar MMP-9 pada pasien leukemia limfoblastik akut-L1 (LLA-L1).Metode: Penelitian dengan metode kohort prospektif telah di lakukan di RSUP Dr Wahidin Sudirohusodo, Makassar dari bulan Augustus sampai Desember 2014. Jumlah pasien LLA sebanyak 20 orang yang dikelompokkan menjadi risiko tinggi (RT) dan risiko biasa (RB). Luaran pasien di kelompokkan menjadi remisi dan tidak remisi setelah kemoterapi fase induksi.Hasil: Pada kelompok LLA dengan RT dan RB masing-masing terdiri dari 6(30%) dan 14(70%). Hasil analisis statistik menunjukkan tidak terdapat perbedaan bermakna kadar MMP-9 antara kelompok RT dan RB sebelum dan sesudah kemoterapi fase induksi dengan nilai p=0.216 dan 0.68, perubahan kadar MMP-9 antara RT dan RB sebelum dan sesudah kemoterapi fase induksi dengan nilai p=0.60 dan 0.975, kadar MMP-9 sebelum kemoterapi fase induksi antara kelompok remisi dan yang tidak remisi dengan nilai p=0.614 dan kadar MMP-9 sebelum kemoterapi fase induksi antara kelompok RT dan RB dengan nilai p=0.402 (p>0.05).Kesimpulan: Tidak terdapat perbedaan bermakna kadar MMP-9 antara kelompok RT dan RB sebelum dan sesudah kemoterapi fase induksi, perubahan kadar MMP-9 pada kelompok RT dan RB sebelum dan sesudah kemoterapi fase induksi, kadar MMP-9 sebelum kemoterapi fase induksi anrata kelompok remisi dan tidak remisi, kadar MMP-9 pada yang remisi antara kelompok RT dan RB.

---

ABSTRACTBack ground: The main role of matrix metalloproteinase-9 (MMP-9) in invasive and infiltration is degradation of extracellular matrix. The objective of this study was to evaluate the serum level of MMP-9 in children with acute lymphoblastic leukemia-L1 (ALL-L1) as prognostic marker.Methods: A prospective cohort study was conducted in Dr Wahidin Sudirohusodo General Hospital, Makassar from August to December to 2014. Twenty patients were enrolled and devided into high risk (HR) and standard risk (SR) ALL group. In terms of outcome, patients were classified into remission and non-remission induction phase of chemotherapy.Result: High risk and SR ALL group consisted of 6(30%) and 14(70%) patients respectively. Statistical analysis showed no significant differences levels of MMP-9 between HR and SR groups before and after induction phase of chemotherapy with p=0.216 and 0.68, changes levels of MMP-9 between HR and SR groups before and after induction phase of chemotherapy with p=0.60 and 0.975, levels of MMP-9 before induction phase of chemotherapy between remission and non-remission groups with p=0.614 and levels of MMP-9 before induction phase chemotherapy in remission between HR and SR groups with p=0.402 (p>0.05).Conclusion: MMP-9 expression was no significant difference in HR and SR groups before and after induction phase of chemotherapy, changes MMP-9 expression between HR and SR before and after induction phase of chemotherapy, MMP-9 expression between remission and non-remission groups and MMP-9 expression in remission between HR and SR groups.;"

"Latar Belakang. Peningkatan jumlah penderita ulkus kaki diabetes berdasarkan data epidemiologi saat ini ternyata setiap tahunnya terus meningkat. Faktor genetik berperan dalam proses penyembuhan luka ulkus kaki diabetes dan peranan faktor genetik terhadap penyembuhan luka penderita ulkus kaki diabetes belum banyak diteliti terutama di Indonesia. Matrix Metalloproteinases MMPs merupakan proteolitik enzim yang memegang peranan pada proses remodeling connective tissue dan degradasi extracellular matrix. Polimorfisme pada gen MMP-9 diduga kuat mempengaruhi proses terjadinya ulkus dan proses penyembuhan luka pada penderita ulkus kaki diabetes. Metode Penelitian: Tujuan penelitian ini adalah menganalisis hubungan polimorfisme gen Matrix metalloprotein- 9 -1562 C>T dan 836 A>G dengan perkembangan penyembuhan luka ulkus kaki penderita diabetes mellitus tipe 2. Rancangan penelitian adalah sebuah penelitian prospektif potong lintang. Penelitian ini dilakukan di Divisi Bedah Vaskular dan Endovaskular FKUI/RSCM Jakarta bekerjasama dengan Laboratorium Biologi Biomolekuler FKUI/RSCM Jakarta selama periode September 2016 - Desember 2016. Populasi target adalah penduduk Jakarta, populasi terjangkau adalah pasien Ulkus Diabetik yang berobat di divisi bedah vascular dan endovascular FKUI/RSCM Jakarta. Besar sampel ditentukan berdasarkan formula uji hipotesis dua proporsi. Dilakukan analisis DNA dan polimorfisme gen MMP-9. Dilakukan dokumentasi foto klinis luka ulkus kaki diabetes pada saat luka sebelum debrideman dan di hari ke 21, kemudian diukur luas luka dan jaringan granulasi dengan menggunakan program ImageJ. Hasil: Perkembangan penyembuhan luka terdapat pada Polimorfisme gen Matrix Metalloprotein-1562C>T CC yaitu sebanyak 17 dari 32 orang 31,48 , CT yaitu sebanyak 9 dari 21 orang 16,67, hasil uji statistik dengan nilai p=0,477. Polimorfisme gen Matrix Metalloprotein 836A>G AA yaitu sebanyak 10 dari 14 orang 18,52, AG yaitu sebanyak 9 dari 19 orang 16,67, GG yaitu 7 dari 21 orang 12,96, Hasil uji statistik p = 0,087.Kesimpulan. Kedua polimorfisme gen MMP-9 tersebut tidak terdapat hubungan bermakna.

---

Background: According to epidemiology data, amount of diabetic ulcer patients is continue to increase. Genetic factor has a role in diabetic foot ulcer healing and the role of genetic it self in managing the ulcer only has a few study or publication conducted in Indonesia. Matrix Metalloproteinase MMPs is the proteolytic enzyme which has role in connective tissue remodeling process and extracellular matrix degradation. MMP 9 genes polymorphism is strongly predicted influencing ulcer formation process and ulcer healing process in diabetic foot ulcer patients.

Methods: The goal of this study is to analyze the relation between MMP 9 genes polymorphism with the progress of ulcer healing di diabetic foot ulcer patient. This is a cross sectional prospective study design at Vascular surgery and Endovascular division, surgery department FKUI RSCM Jakarta cooperated with Biology Biomolecular laboratory at FKUI RSCM during September december 2016. Target population are all Jakarta citizens, and accessible population are all diabetic foot ulcer patients in Vascular surgery and Endovascular division FKUI RSCM, Jakarta. Sample size is determined based on dual proportion hypothesis test formula. Blood sample are taken and sent to biology medic laboratory to perform DNA and MMP 9 gene polymorphism analysis. The characteristic of ulcer is documented before and on day 21, then the ulcer size and granulation tissue are measured using ImageJ program.

Results: Improvement of healing ulcer in gene polymorphism of matrix metalloproteinase 1562C T CC is about 17 from 32 patients 31,48 , CT is about 9 from 21 patients 16,67 , statistic testing with p value 0,477. Gene polymorphism metalloproteinase 836A G AA is 10 from 14 patienrs 18,52, AG is 9 from 19 patients 16,67, GG is 7 from 21 patients 12,96, statistic testing with p value 0,087.Conclusions There are not significant relationship in both of MMP 9 gene polymorfsm with diabetic foot ulcer healing progress"

"Infeksi virus hepatitis B (VHB) merupakan masalah kesehatan global. Terapi yang ada saat ini hanya berdampak minimal terhadap covalently closed circular deoxyribonucleic acid (cccDNA), sehingga eradikasi sulit dicapai. Matriks Metaloproteinase-9 (MMP-9) berperan dalam meningkatkan replikasi VHB, namun belum ada penelitian yang mengevaluasi peran penghambat MMP-9 terhadap replikasi VHB. Kultur primer hepatosit diperoleh dari Tupaia javanica dan diinfeksi dengan VHB manusia, kemudian dibagi menjadi dua kelompok, yaitu kontrol dan intervensi. Kelompok intervensi diberikan penghambat MMP-9 dosis 1 nM, 3 nM, dan 7 nM. Peripheral blood mononuclear cells (PBMC) manusia diperoleh dari pasien hepatitis B kronik, kemudian dibagi menjadi dua kelompok, yaitu kontrol dan intervensi. Kelompok intervensi diberikan penghambat MMP-9 dosis 3 nM. Dilakukan pengukuran HBsAg, DNA VHB, cccDNA, MMP-9, type-1 IFN receptor 1 (IFNAR1), dan interferon-β (IFN-β) sebelum dan 72 jam setelah pemberian intervensi pada kedua kelompok. Pada kultur primer hepatosit T. javanica yang diinfeksi VHB manusia, pemberian penghambat MMP-9 dosis 1 nM, 3 nM, dan 7 nM secara konsisten menurunkan kadar HBsAg, DNA VHB, cccDNA, dan MMP-9. Dosis 3 nM meningkatkan kadar IFNAR1, sedangkan dosis 7 nM meningkatkan kadar IFN-β. Dosis 3 nM menunjukkan efek yang lebih optimal dibandingkan dosis lainnya. Pada PBMC manusia dengan infeksi VHB, pemberian penghambat MMP- 9 dosis 3 nM menurunkan kadar HBsAg, DNA VHB, cccDNA, dan MMP- 9, serta meningkatkan kadar IFN-β, namun menurunkan kadar IFNAR1. Studi ini menunjukkan bahwa pemberian penghambat MMP-9 dapat menurunkan kadar HBsAg, DNA VHB, cccDNA, dan MMP-9, serta meningkatkan kadar IFN-β pada kultur primer hepatosit T. javanica dan PBMC manusia.

---

Hepatitis B virus (HBV) infection remains a significant global health concern. Current therapies have minimal impact on covalently closed circular deoxyribonucleic acid (cccDNA), making HBV eradication difficult. Matrix Metalloproteinase-9 (MMP-9) enhance HBV replication, but its inhibition has not been studied. Primary hepatocyte cultures were obtained from Tupaia javanica and infected with human HBV, then divided into control and intervention groups. The intervention groups were treated with MMP-9 inhibitors at doses of 1 nM, 3 nM, and 7 nM. Human peripheral blood mononuclear cells (PBMC) were isolated from chronic hepatitis B patients and divided into control and intervention groups. The intervention groups received MMP-9 inhibitors at dose of 3 nM. Measurements of HBsAg, HBV DNA, cccDNA, MMP-9, type-1 IFN receptor 1 (IFNAR1), and interferon-β (IFN-β) were performed before and 72 hours after intervention in both groups. In T. javanica primary hepatocyte culture infected with human HBV, MMP-9 inhibitors at doses of 1 nM, 3 nM, and 7 nM consistently decreased levels of HBsAg, HBV DNA, cccDNA, and MMP-9. The 3 nM dose increased IFNAR1 levels, while the 7 nM dose increased IFN-β levels. The 3 nM dose demonstrated the most optimal effects. In human PBMC with HBV infection, MMP-9 inhibitor at dose of 3 nM decreased levels of HBsAg, HBV DNA, cccDNA, MMP-9, increased IFN-β levels, but reduced IFNAR1 levels. This study shows that administration of MMP-9 inhibitors reduced levels of HBsAg, HBV DNA, cccDNA, and MMP-9, while increased IFN-β levels in T. javanica primary hepatocyte cultures and human PBMC."